The Goldman Sachs Group Has Lowered Expectations for Viridian Therapeutics (NASDAQ:VRDN) Stock Price

Viridian Therapeutics (NASDAQ:VRDN) had its price target dropped by The Goldman Sachs Group from $41.00 to $36.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 81.70% from the stock’s current price.

Several other equities analysts have also weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Viridian Therapeutics in a research report on Wednesday, January 21st. UBS Group initiated coverage on shares of Viridian Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $50.00 target price on the stock. Royal Bank Of Canada reduced their target price on shares of Viridian Therapeutics from $45.00 to $42.00 and set an “outperform” rating for the company in a research report on Friday, February 27th. Wells Fargo & Company decreased their price target on shares of Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating for the company in a research note on Tuesday. Finally, Needham & Company LLC lowered their price target on shares of Viridian Therapeutics from $42.00 to $32.00 and set a “buy” rating on the stock in a report on Monday. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $39.21.

Viridian Therapeutics Stock Performance

Shares of VRDN traded up $1.28 on Tuesday, reaching $19.81. 1,317,251 shares of the company’s stock traded hands, compared to its average volume of 1,637,400. The stock’s 50 day simple moving average is $29.42 and its two-hundred day simple moving average is $27.88. The stock has a market cap of $2.03 billion, a PE ratio of -6.00 and a beta of 1.00. Viridian Therapeutics has a 52-week low of $9.90 and a 52-week high of $34.29. The company has a current ratio of 12.65, a quick ratio of 12.65 and a debt-to-equity ratio of 0.08.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.18). Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%.The business had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $15.75 million. On average, analysts forecast that Viridian Therapeutics will post -4.03 earnings per share for the current fiscal year.

Insider Buying and Selling at Viridian Therapeutics

In other news, insider Jennifer Tousignant sold 2,272 shares of Viridian Therapeutics stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $31.16, for a total value of $70,795.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.65% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of VRDN. Perceptive Advisors LLC raised its holdings in Viridian Therapeutics by 108.1% during the 4th quarter. Perceptive Advisors LLC now owns 3,042,703 shares of the company’s stock valued at $94,689,000 after acquiring an additional 1,580,303 shares during the period. Morgan Stanley boosted its holdings in shares of Viridian Therapeutics by 805.6% in the fourth quarter. Morgan Stanley now owns 1,738,225 shares of the company’s stock worth $54,094,000 after acquiring an additional 1,546,284 shares during the period. Avoro Capital Advisors LLC bought a new position in shares of Viridian Therapeutics in the fourth quarter worth $46,680,000. Vanguard Group Inc. grew its position in shares of Viridian Therapeutics by 29.6% in the fourth quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock valued at $174,650,000 after purchasing an additional 1,280,161 shares in the last quarter. Finally, Commodore Capital LP raised its stake in shares of Viridian Therapeutics by 35.4% during the 2nd quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock valued at $68,152,000 after purchasing an additional 1,275,000 shares during the period.

More Viridian Therapeutics News

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: REVEAL‑1 met its primary endpoint: elegrobart showed statistically significant proptosis responder rates (54% Q4W and 63% Q8W vs 18% placebo at week 24), providing a clear clinical efficacy signal for the subcutaneous candidate. Business Wire
• Positive Sentiment: Wedbush trimmed its price target (from $44 to $37) but kept an “outperform” rating — the new target implies roughly ~95% upside from current levels, signaling continued bullish conviction from a major shop. Benzinga
• Positive Sentiment: Needham cut its target (from $42 to $32) but maintained a “buy” rating, leaving a large implied upside (~67%), which likely supports near‑term buying interest after the sell‑off. Benzinga
• Neutral Sentiment: VRDN was mentioned on market roundups and podcasts (Bloomberg, Seeking Alpha) as a notable mover after the REVEAL‑1 release — these keep the name in traders’ screens but don’t change fundamentals directly. Bloomberg Podcast
• Negative Sentiment: Despite the positive readout, the stock plunged (>30%) on initial reaction as some investors parsed details (magnitude of effect by dosing arm, safety/labeling questions, or commercial assumptions). This swift sell‑off is a key reason for heightened volatility. Proactive Investors
• Negative Sentiment: Multiple news outlets highlighted the disconnect — “stock tumbles despite trial success” — reflecting investor concern or uncertainty about regulatory path, market uptake, or trial nuances. That narrative pressured the stock before today’s bounce. Investing.com
• Negative Sentiment: Several firms cut price targets: Wells Fargo lowered its target to $20 and set an “equal weight” rating (limited upside), and HC Wainwright trimmed its target to $22 while keeping a “buy” call — the cuts signal moderated near‑term expectations and contributed to selling pressure. Benzinga
• Negative Sentiment: Commentary and headlines from outlets (Bioworld, MSN) emphasized the market “sacking” or “plunging” reaction, reinforcing negative sentiment among short‑term traders. BioWorld

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.